颜红兵,霍勇

• 1:中国医学科学院阜外医院深圳医院
• 2:北京大学第一医院心内科

摘要(Abstract)：

如何优化经皮冠状动脉介入治疗术后抗血小板治疗始终是临床实践日常面对的问题。2023年的研究方向主要集中在评估缩短双联抗血小板治疗时间、无阿司匹林的P2Y12受体拮抗剂单药治疗策略和降级抗血小板治疗方案的效能和安全性，为临床应用这些策略提供了更多的循证医学证据。未来的方向将包括关注新的治疗靶点、开发新的抗血小板药物、使用现有药物实施新的抗血栓治疗方案以及进一步验证现代抗血小板策略。

关键词(KeyWords)： 经皮冠状动脉介入治疗;抗血小板治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 颜红兵,霍勇

参考文献(References)：

• [1]Faridi KF,Strom JB,Kundi H,et al.Association between claimsdefined frailty and outcomes following 30 versus 12 months of dual antiplatelet therapy after percutaneous coronary intervention:findings from the EXTEND-DAPT study[J].J Am Heart Assoc,2023,12(14):e029588.DOI:10.1161/JAHA.123.029588.
• [2]Rymer JA,Wegermann ZK,Kaltenbach LA,et al.Challenge in predicting persistence to P2Y_(12)inhibitors:a perspective from the ARTEMIS trial[J].J Am Heart Assoc,2023,12(12):e029063.DOI:10.1161/JAHA.122.029063.
• [3]Bongiovanni D,Schreiner N,Gosetti R,et al.Immature platelet fraction predicts adverse events in patients with acute coronary syndrome:the ISAR-REACT 5 reticulated platelet substudy[J].Arterioscler Thromb Vasc Biol,2023,43(2):e83-e93.DOI:10.1161/ATVBAHA.122.318614.
• [4]Angiolillo DJ,Cao D,Sartori S,et al.Dyspnea-related ticagrelor discontinuation after percutaneous coronary intervention[J].JACC Cardiovasc Interv,2023,16(20):2514-2524.DOI:10.1016/j.jcin.2023.08.019.
• [5]Han JK,Hwang D,Yang S,et al.Comparison of 3-to 6-month versus 12-month dual antiplatelet therapy after coronary intervention using the contemporary drug-eluting stents with ultrathin struts:the HOST-IDEA randomized clinical trial[J].Circulation,2023,147(18):1358-1368.DOI:10.1161/CJRCULATIONAHA.123.064264.
• [6]Costa F,Montalto C,Branca M,et al.Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk:a meta-analysis of randomized trials[J].Eur Heart J,2023,44(11):954-968.DOI:10.1093/eurheartj/ehac706.
• [7]Landi A,Heg D,Frigoli E,et al.Abbreviated or standard antiplatelet therapy in HBR patients:final 15-month results of theMASTER-DAPT trial[J].JACC Cardiovasc Interv,2023,16(7):798-812.DOI:10.1016/j.jcin.2023.01.366.
• [8]Lee B,Lee SJ,Kim BK,et al.Sex differences in outcomes of ticagrelor therapy with or without aspirin after percutaneous coronary intervention in patients with acute coronary syndrome:a post hoc secondary analysis of the TICO randomized clinical trial[J].Arterioscler Thromb Vasc Biol,2023,43(6):e218-e226.DOI:10.1161/ATVBAHA.122.318725.
• [9]Valgimigli M,Spirito A,Sartori S,et al.1-or 3-month DAPT in patients with hbr with or without oral anticoagulant therapy after PCI[J].JACC Cardiovasc Interv,2023,16(20):2498-2510.DOI:10.1016/j.jcin.2023.08.014.
• [10]Gragnano F,Mehran R,Branca M,et al.P2Y_(12)inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions[J].J Am Coll Cardiol,2023,81(6):537-552.DOI:10.1016/jjacc.2022.11.041.
• [11]Yang S,Kang J,Park KW,et al.Comparison of antiplatelet monotherapies after percutaneous coronary intervention according to clinical,ischemic,and bleeding risks[J].J Am Coll Cardiol,2023,82(16):1565-1578.DOI:10.1016/j.jacc.2023.07.031.
• [12]Mendieta G,Mehta S,Baber U,et al.Bleeding and ischemic risks of ticagrelor monotherapy after coronary interventions[J].J Am Coll Cardiol,2023,82(8):687-700.DOI:10.1016/j.jacc.2023.05.062.
• [13]Gragnano F,Cao D,Pirondini L,et al.P2Y_(12)inhibitor or aspirin monotherapy for secondary prevention of coronary events[J].J Am Coll Cardiol,2023,82(2):89-105.DOI:10.1016/j.jacc.2023.04.051.
• [14]Kang J,Park KW,Lee H,et al.Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention:the HOST-EXAM extended study[J].Circulation,2023,147(2):108-117.DOI:10.1161/CIRCULATIONAHA.122.062770.
• [15]Yamamoto K,Watanabe H,Morimoto T,et al.Clopidogrel monotherapy after 1-month dual antiplatelet therapy in patients with diabetes undergoing percutaneous coronary intervention[J].JACC Cardiovasc Interv,2023,16(1):19-31.DOI:10.1016/j.jcin.2022.09.053.
• [16]Rhee TM,Bae JW,Park KW,et al.Aspirin vs.clopidogrel for long-term maintenance after coronary stenting in patients with diabetes:a post hoc analysis of the HOST-EXAM trial[J].JAMA Cardiol,2023,8(6):535-544.DOI:10.1001/jamacardio.2023.0592.
• [17]Wu H,Xu L,Zhao X,et al.Indobufen or aspirin on top of clopidogrel after coronary drug-eluting stent implantation(OPTION):a randomized,open-label,end point-blinded,noninferiority trial[J].Circulation,2023,147(3):212-222.DOI:10.1161/CIRCUL ATION AHA.122.062762.
• [18]Lee SY,Jeong YH,Yun KH,et al.P2Y_(12)inhibitor monotherapy combined with colchicine following PCI in ACS patients:the MACT pilot study[J].JACC Cardiovasc Interv,2023,16(15):1845-1855.DOI:10.1016/j.jcin.2023.05.035.
• [19]Kuno T,Watanabe A,Shoji S,et al.Short-term DAPT and DAPT de-escalation strategies for patients with acute coronary syndromes:a systematic review and network meta-analysis[J].Circ Cardiovasc Interv,2023,16(9):e013242.DOI:10.1161/CIRCINTERVENTIONS.123.013242.
• [20]Kang J,Rizas KD,Park KW,et al.Dual antiplatelet therapy deescalation in acute coronary syndrome:an individual patient metaanalysis[J].Eur Heart J,2023,44(15):1360-1370.DOI:10.1093/eurheartj/ehac829.
• [21]Ingraham BS,Farkouh ME,Lennon RJ,et al.Genetic-guided oral P2Y_(12)inhibitor selection and cumulative ischemic events after percutaneous coronary intervention[J].JACC Cardiovasc Interv,2023,16(7):816-825.DOI:10.1016/j.jcin.2023.01.356.